LOGIN  |  REGISTER
Viking Therapeutics

InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

November 05, 2025 | Last Trade: US$13.74 0.31 -2.21

YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025.

Third Quarter 2025 Highlights:

  • Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.
  • Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.
  • GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.
  • Total cash position of $532.3 million as of September 30, 2025, including cash and cash equivalents, marketable securities and short-term bank deposits.

U.S. GAAP Results

(U.S. dollars in thousands, except for per share data)

 

 Q3 2025

 Q3 2024

Revenues

$93,165

$130,232

(including $31.9M of pre-order sales)

Gross Margins

78 %

82 %

Net Income

$21,863

$50,990

Earnings per Diluted Share

$0.34

$0.65

*Non-GAAP Results

(U.S. dollars in thousands, except for per share data)

 

Q3 2025

Q3 2024

Gross Margins

78 %

82 %

Net Income

$24,532

$54,971

Earnings per Diluted Share

$0.38

$0.70

 

*Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation and related tax adjustments.

Management Comments

"The third quarter progressed in line with our expectations, even as broader economic conditions continued to present challenges," said Moshe Mizrahy, Chief Executive Officer of InMode. "Consumer sentiment remains cautious, and global uncertainties persist. Nonetheless, our team remains focused, executing with discipline and investing in the strategic areas that will fuel our long-term trajectory.

"On the corporate front, we are excited to welcome Michael Dennison as our new President of North America.  Michael has been with InMode since 2018 and his proven leadership and industry expertise will be instrumental in advancing our regional strategy, deepening customer engagement, and supporting InMode's sustainable growth," Mizrahy concluded.

Yair Malca, Chief Financial Officer of InMode, added, "Gross margins in the third quarter were in line with expectations and reflected our proactive planning around tariff impacts."

Third Quarter 2025 Financial Results

Total revenues for the third quarter of 2025 were $93.2 million.  In the third quarter of 2024, revenues were $130.2 million (including $31.9 million in revenue from first half of 2024 pre-orders). 

GAAP and a *non-GAAP gross margin for the third quarter was 78%, compared to a gross margin of 82% for the third quarter of 2024.

GAAP operating margin for the third quarter of 2025 was 22%, compared to 37% in the third quarter of 2024. *Non-GAAP operating margin for the third quarter of 2025 was 25%, compared to 40% for the third quarter of 2024.

GAAP operating margin for the nine months ended September 30, 2025, was 22% compared to 29% for the same period in 2024. *Non-GAAP operating margin for the nine months ended September 30, 2025, was 26% compared to 33% for the same period in 2024. The decline in operating margins across both the quarterly and year-to-date periods primarily reflects lower sales in the U.S., which is the company's most profitable region.

InMode reported GAAP net income of $21.9 million, or $0.34 per diluted share, in the third quarter of 2025, compared to $51.0 million, or $0.65 per diluted share, in the third quarter of 2024. On a *non-GAAP basis, InMode reported net income of $24.5 million, or $0.38 per diluted share, in the third quarter of 2025, compared to $55.0 million, or $0.70 per diluted share, in the third quarter of 2024.

As of September 30, 2025, InMode had cash and cash equivalents, marketable securities and short-term bank deposits of $532.3 million.

2025 Financial Outlook

Management provided an outlook for the full year of 2025 ending December 31, 2025. Based on our current estimates, management expects:

  • Revenues remain the same as in previous guidance between $365 million to $375 million
  • *Non-GAAP gross margin remains the same as in previous guidance between 78% and 80%
  • *Non-GAAP income from operations remains the same as in previous guidance to be between $93 million and $98 million
  • *Non-GAAP earnings per diluted share remain the same as in previous guidance between $1.55 to $1.59

This outlook is not a guarantee of future performance, and stockholders should not rely on such forward-looking statements. See "Forward-Looking Statements" for additional information.

*Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation and related tax adjustments.

The Current Situation in Israel

Regarding the current situation in Israel, on October 10, 2025, a new cease-fire agreement between Hamas and Israel began, and the hostilities have formally paused after two years of conflicts. The scope and severity of ongoing conflicts in Gaza, Northern Israel, Lebanon, Iran, and the broader region are unpredictable and could escalate any time. To date, our operations have not been materially affected. We continue to monitor political and military developments closely and examine the consequences for our operations and assets. 

Use of Non-GAAP Financial Measures

In addition to InMode's operating results presented in accordance with GAAP, this release contains certain non-GAAP financial measures including non-GAAP net income, non-GAAP earnings per diluted share, non-GAAP operating margin. Because these measures are used in InMode's internal analysis of financial and operating performance, management believes they provide investors with greater transparency of its view of InMode's economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode's GAAP operating results, allows investors to more effectively evaluate and compare InMode's performance to that of its peers, although InMode's presentation of its non-GAAP measures may not be strictly comparable to the similarly titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.

Conference Call Information

Mr. Moshe Mizrahy, Chief Executive Officer, Dr. Michael Kreindel, Co-Founder and Chief Technology Officer, Mr. Yair Malca, Chief Financial Officer will host a conference call today, November 5, 2025, at 8:30 a.m. Eastern Time to discuss the third quarter 2025 financial results.

The Company encourages participants to pre-register for the conference call using the following link

https://dpregister.com/sreg/10202681/ffd9babcf8. Callers will receive a unique dial-in number upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

For callers who opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

U.S. Toll-Free Dial-in Number: 1-833-316-0562
Israel Toll- Free Dial-in Number: 1-80-921-2373
International Dial-in Number: 1-412-317-5736
Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=JfIdKlTZ
At:
8:30 a.m. Eastern Time
5:30 a.m. Pacific Time

The conference call will also be webcast live from a link on InMode's website at https://inmodeinvestors.com/events-presentations/. A replay of the conference call will be available from November 5, 2025, at 12 p.m. Eastern Time to November 19, 2025, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers: 

Replay Dial-in U.S TOLL-FREE: 1-877-344-7529
Replay Dial-in Canada TOLL-FREE: 1-855-669-9658
Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088
Replay Pin Number: 2676014

To access the replay using an international dial-in number, please select the link below:
https://services.choruscall.com/ccforms/replay.html

A replay of the conference call will also be available for 90 days on InMode's website at https://inmodeinvestors.com/events-presentations/.

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

Forward-Looking Statements

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2025 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 4, 2025, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

Company Contact:
Yair Malca
Chief Financial Officer
Phone: (949) 305-0108
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Relations Contact:
Miri Segal
MS-IR LLC
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

INMODE LTD.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(U.S. dollars in thousands, except for per share data)
(Unaudited)

 
 

Three months ended
September 30,

 

Nine months ended
September 30,

 

2025

 

2024

 

2025

 

2024

 

REVENUES

93,165

 

130,232

 

266,641

 

296,965

 

COST OF REVENUES

20,856

 

24,055

 

56,971

 

57,536

 

GROSS PROFIT

72,309

 

106,177

 

209,670

 

239,429

 

OPERATING EXPENSES:

        

Research and development

3,543

 

3,254

 

9,810

 

10,470

 

Sales and marketing

44,970

 

51,863

 

132,171

 

136,713

 

General and administrative

2,899

 

2,799

 

8,293

 

7,579

 

TOTAL OPERATING EXPENSES

51,412

 

57,916

 

150,274

 

154,762

 

OPERATIONS INCOME

20,897

 

48,261

 

59,396

 

84,667

 

Finance income, net

4,721

 

9,918

 

19,642

 

26,592

 

INCOME BEFORE INCOME TAXES

25,618

 

58,179

 

79,038

 

111,259

 

INCOME TAXES

3,755

 

7,189

 

12,232

 

12,755

 

NET INCOME

21,863

 

50,990

 

66,806

 

98,504

 
         

EARNINGS PER SHARE:

        

Basic

0.35

 

0.66

 

1.03

 

1.20

 

Diluted

0.34

 

0.65

 

1.02

 

1.19

 

WEIGHTED AVERAGE NUMBER OF SHARES
OUTSTANDING USED IN COMPUTATION OF
EARNINGS PER SHARE (in thousands)

        

Basic

63,291

 

77,022

 

65,072

 

81,795

 

Diluted

63,868

 

77,908

 

65,727

 

83,016

 

 

INMODE LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except for per share data)
(Unaudited)

 
 

September 30,

2025

 

December 31,

2024

Assets

   

CURRENT ASSETS:

   

Cash and cash equivalents

252,437

 

155,329

Marketable securities

121,518

 

267,688

Short-term bank deposits

158,353

 

173,455

Accounts receivable, net of allowance for credit losses

38,095

 

36,335

Prepaid expense and other receivables

24,485

 

22,097

Inventories

71,403

 

59,548

     TOTAL CURRENT ASSETS

666,291

 

714,452

    NON-CURRENT ASSETS:

   

Accounts receivable, net of allowance for credit losses

2,350

 

3,176

Deferred income tax asset

54,104

 

56,285

Operating lease right-of-use assets

8,922

 

8,732

Property and equipment, net

2,238

 

2,322

Other investments

700

 

700

TOTAL NON-CURRENT ASSETS

68,314

 

71,215

TOTAL ASSETS

734,605

 

785,667

Liabilities and shareholders' equity

   

CURRENT LIABILITIES:

   

Accounts payable

16,723

 

13,782

Contract liabilities

15,099

 

16,755

Other liabilities

36,508

 

39,314

TOTAL CURRENT LIABILITIES

68,330

 

69,851

    NON-CURRENT LIABILITIES:

   

Contract liabilities

3,126

 

3,336

Other liabilities

4,171

 

3,356

Operating lease liabilities

5,593

 

5,311

TOTAL NON-CURRENT LIABILITIES

12,890

 

12,003

TOTAL LIABILITIES

81,220

 

81,854

    

TOTAL SHAREHOLDERS' EQUITY

653,385

 

703,813

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

734,605

 

785,667

INMODE LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in thousands, except for per share data)
(Unaudited)

 
  

Three months ended
September 30,

 

Nine months ended
September 30,

 

2025

 

2024

 

2025

 

2024

 

CASH FLOWS FROM OPERATING ACTIVITIES:

        

Net income

21,863

 

50,990

 

66,806

 

98,504

 

Adjustments required to reconcile net income to net cash provided by operating activities:

        

Depreciation and amortization

156

 

138

 

521

 

480

 

Share-based compensation expenses

2,696

 

3,981

 

8,632

 

13,122

 

Change in allowance for credit losses of trade receivable

106

 

130

 

159

 

414

 

Loss on marketable securities, net

11

 

29

 

14

 

170

 

Finance expenses (income), net

3,147

 

3,863

 

1,260

 

(5,934)

 

Deferred income taxes

602

 

35

 

2,064

 

(58)

 

Changes in operating assets and liabilities:

        

Decrease (increase) in accounts receivable

(2,353)

 

(2,570)

 

(1,094)

 

1,924

 

Increase in other receivables

(147)

 

(860)

 

(2,403)

 

(7,577)

 

Increase in inventories

(3,293)

 

(5,657)

 

(11,855)

 

(13,189)

 

Increase (decrease) in accounts payable

(759)

 

(1,235)

 

2,941

 

347

 

Increase (decrease) in other liabilities

564

 

11,722

 

(2,596)

 

6,160

 

Increase (decrease) in contract liabilities (current and non-current)

1,874

 

(26,517)

 

(1,866)

 

5,859

 

Net cash provided by operating activities

24,467

 

34,049

 

62,583

 

100,222

 

CASH FLOWS FROM INVESTING ACTIVITIES:

        

Investment in short-term deposits

(153,904)

 

(78,390)

 

(178,904)

 

(164,687)

 

Proceeds from short-term deposits

103,390

 

138,140

 

189,687

 

151,640

 

Purchase of fixed assets

(134)

 

(77)

 

(438)

 

(435)

 

Purchase of marketable securities

-

 

(90,820)

 

(20,877)

 

(276,513)

 

Proceeds from sale of marketable securities

14,211

 

22,233

 

17,214

 

69,608

 

Proceeds from maturity of marketable securities

48,105

 

122,969

 

152,127

 

304,777

 

Net cash provided by investing activities

11,668

 

114,055

 

158,809

 

84,390

 

CASH FLOWS FROM FINANCING ACTIVITIES:

        

 Repurchase of ordinary shares

-

 

(76,556)

 

(127,444)

 

(165,536)

 

    Exercise of options

249

 

565

 

1,248

 

1,194

 

Net cash provided by (used in) financing activities

249

 

(75,991)

 

(126,196)

 

(164,342)

 

EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS

(184)

 

728

 

1,912

 

157

 

NET INCREASE IN CASH AND CASH EQUIVALENTS

36,200

 

72,841

 

97,108

 

20,427

 
         

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

216,237

 

91,997

 

155,329

 

144,411

 

CASH AND CASH EQUIVALENTS AT END OF PERIOD

252,437

 

164,838

 

252,437

 

164,838

 

INMODE LTD.

CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS
(U.S. dollars in thousands, except for per share data)
(Unaudited)

  

Three months ended September 30, 

 

Nine months ended September 30,

2025

 
 

2024

 

2025

 
 

2024

 

Revenues by Category: 

               

Capital Equipment revenues - United States

45,203

 

49 %

 

85,734

 

66 %

 

1,15,398

 

44 %

 

1,51,392

 

51 %

Capital Equipment revenues - International

28,063

 

30 %

 

28,662

 

22 %

 

91,329

 

34 %

 

86,191

 

29 %

 

Total Capital Equipment revenues 

 

73,266

  

79 %

  

1,14,396

  

88 %

  

2,06,727

  

78 %

  

2,37,583

  

80 %

Consumables and service revenues

19,899

 

21 %

 

15,836

 

12 %

 

59,914

 

22 %

 

59,382

 

20 %

 

Total Revenue 

 

93,165

  

100 %

  

1,30,232

  

100 %

  

2,66,641

  

100 %

  

2,96,965

  

100 %

 

Three months ended September 30,

 

Nine months ended September 30,

2025

 

2024

 

2025

 

2024

 

%

 

%

 

%

 

%

 

United
States

 

International

 

Total

 

United
States

 

International

 

Total

 

United
States

 

International

 

Total

 

United
States

 

International

 

Total

Revenues by Technology:

                       

Minimal-Invasive

75

 

76

 

75

 

95

 

77

 

90

 

79

 

79

 

80

 

90

 

82

 

88

Hands-Free

2

 

1

 

2

 

4

 

3

 

4

 

3

 

2

 

2

 

7

 

3

 

5

Non-Invasive

23

 

23

 

23

 

1

 

20

 

6

 

18

 

19

 

18

 

3

 

15

 

7

 

100

 

100

 

100

 

100

 

100

 

100

 

100

 

100

 

100

 

100

 

100

 

100

INMODE LTD.

 

RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF
INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME 
(U.S. dollars in thousands, except for per share data)
 (Unaudited)

 

 
 
 

Three months ended September 30, 2025

 

Three months ended September 30, 2024

 
 

GAAP

 

Share Based
Compensation

 

Non-GAAP

 

GAAP

 

Share Based
Compensation

 

Non-GAAP

 

REVENUES

93,165

 

-

 

93,165

 

130,232

 

-

 

130,232

 

COST OF REVENUES

20,856

 

(343)

 

20,513

 

24,055

 

(481)

 

23,574

 

GROSS PROFIT

72,309

 

343

 

72,652

 

106,177

 

481

 

106,658

 

OPERATING EXPENSES:

            

Research and development

3,543

 

(274)

 

3,269

 

3,254

 

(890)

 

2,364

 

Sales and marketing

44,970

 

(1,804)

 

43,166

 

51,863

 

(2,300)

 

49,563

 

General and administrative

2,899

 

(275)

 

2,624

 

2,799

 

(310)

 

2,489

 

TOTAL OPERATING
EXPENSES

51,412

 

(2,353)

 

49,059

 

57,916

 

(3,500)

 

54,416

 

OPERATIONS INCOME

20,897

 

2,696

 

23,593

 

48,261

 

3,981

 

52,242

 

Finance income, net

4,721

 

-

 

4,721

 

9,918

 

-

 

9,918

 

INCOME BEFORE INCOME TAXES

25,618

 

2,696

 

28,314

 

58,179

 

3,981

 

62,160

 

INCOME TAXES

3,755

 

27

 

3,782

 

7,189

 

-

 

7,189

 

NET INCOME

21,863

 

2,669

 

24,532

 

50,990

 

3,981

 

54,971

 

EARNINGS PER SHARE:

            

Basic

0.35

   

0.39

 

0.66

   

0.71

 

Diluted

0.34

   

0.38

 

0.65

   

0.70

 

WEIGHTED AVERAGE NUMBER OF
SHARES OUTSTANDING USED IN
COMPUTATION OF EARNINGS PER
SHARE (in thousands)

            

Basic

63,291

   

63,291

 

77,022

   

77,022

 

Diluted

63,868

   

64,531

 

77,908

   

78,548

 

 

 

Nine months ended September 30, 2025

 

Nine months ended September 30, 2024

GAAP

 

Share Based
Compensation

 

Non-GAAP

 

GAAP

 

Share Based
Compensation

 

Non-GAAP

REVENUES

266,641

 

-

 

266,641

 

296,965

 

-

 

296,965

COST OF REVENUES

56,971

 

(987)

 

55,984

 

57,536

 

(1,361)

 

56,175

GROSS PROFIT

209,670

 

987

 

210,657

 

239,429

 

1,361

 

240,790

OPERATING EXPENSES:

           

Research and development

9,810

 

(783)

 

9,027

 

10,470

 

(1,877)

 

8,593

Sales and marketing

132,171

 

(6,096)

 

126,075

 

136,713

 

(9,007)

 

127,706

General and administrative

8,293

 

(766)

 

7,527

 

7,579

 

(877)

 

6,702

TOTAL OPERATING
EXPENSES

150,274

 

(7,645)

 

142,629

 

154,762

 

(11,761)

 

143,001

OPERATIONS INCOME

59,396

 

8,632

 

68,028

 

84,667

 

13,122

 

97,789

Finance income, net

19,642

 

-

 

19,642

 

26,592

 

-

 

26,592

INCOME BEFORE INCOME
TAXES

79,038

 

8,632

 

87,670

 

111,259

 

13,122

 

124,381

INCOME TAXES

12,232

 

(628)

 

11,604

 

12,755

 

-

 

12,755

NET INCOME

66,806

 

9,260

 

76,066

 

98,504

 

13,122

 

111,626

EARNINGS PER
SHARE:

           

Basic

1.03

   

1.17

 

1.20

   

1.36

Diluted

1.02

   

1.15

 

1.19

   

1.34

WEIGHTED AVERAGE
NUMBER OF SHARES
OUTSTANDING USED IN
COMPUTATION OF
EARNINGS PER SHARE (in
thousands)

           

Basic

65,072

   

65,072

 

81,795

   

81,795

Diluted

65,727

   

66,199

 

83,016

   

83,536


C4 Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page